Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Malaria Treatment in Mexico

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Recommended by WHO, http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf?ua=1~1. - Confirmed P. vivax mono- infection by microscopy~2. - Parasitemia, minimum of 500 asexual parasites per µl of blood.~3. - Presence of axillary temperature ≥ 37.5 or history of fever during the past 48 hours~4. - Ability to swallow oral medication~5. - Informed consent from the patient, or from the parent or guardian in the case of children under 7 years old, or both consents by participant and parent for individual´s age ranging within 7 and 18 years old.~6. - Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule.~7. -Patients living in accessible villages, desirable less than 1 hour far from our facility by car.~Exclusion Criteria:~1. - Mixed species infection with another plasmodium species~2. - Presence of signs of danger, or severe malaria, according to the definitions of WHO http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf?ua=1~3. - if they presented signs of severe malnutrition or anemia~4. - had taken an anti-malaria treatment or had a malaria infection within the previous two months.~5. - Pregnant woman or positive pregnant test or breast feeding~6. - History of hypersensitivity to CQ or PQ~7. - Previous malaria attack within one year, identified at the malaria nominal record, sanitary jurisdiction VII of Chiapas, Mexico.~8. - had another cause for their fever or other chronic diseases as hypertension, diabetes, liver or kidney disease, etc.~9. - if they lived in communities at distances farther than one hour by motor vehicle from the facility.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 14-day treatment (T14) (Type: ACTIVE_COMPARATOR): The operational treatment-dose was administered by mouth. The number of tablets of Chloroquine phosphate of 150 mg for three days (x-x-x/ number of tablets of Primaquine (15mg or 5 mg)), daily during 14 days. For 1 year old subjects only chloroquine (1-½-½/ ½ of 5 mg); for 2-5 years old (1-¾-1/ 1 of 5 mg); 6-12 years old (2-1-2/ 2 of 5 mg); 13 years old and over with about 60 kg of body weight (3-2-2/ 1 of 15 mg) and above 60 kg of body weight (4-3-3 / 1 of 15 mg).~According to the age group as indicated by the Mexican guidelines for vector borne diseases control (http://www.salud.gob.mx/unidades/cdi/nom/032ssa202.html) (Table 10)
- Intermittent single doses (ISD) (Type: EXPERIMENTAL): The single dose medication was administered orally according to age group as the operational table: (number of tablets of chloroquine phosphate of 150 mg / number of tablets of primaquine (15mg or 5 mg)): for 1 year old (½ / 1 of 5 mg); for 2¬-5 years old (1 / 2 of 5 mg); 6-12 years old (2 / 4 of 5 mg); 13 years old and over of about 60 kg of body weight (3 / 2 of 15 mg), and above 60 kg of body weight (4 / 3 of 15 mg).~It is administered on Days 0 (after the detection of infection by microscopy), and Days 30, 60, 180, 210, 240 and 360 as indicated in the National guidelines for vector borne diseases control (http://www.salud.gob.mx/unidades/cdi/nom/032ssa202.html).

Based on this trial design, predict the completion outcome and termination type (if applicable).